Abstract
This evidence-based review by Võ Thế Nhân and Võ Hồng Khôi summarizes pharmacological treatment strategies for vestibular disorders and ataxia, emphasizing the "4 Rights" principle: correct diagnosis, correct drug selection, adequate dosage, and appropriate treatment duration. For acute unilateral vestibulopathy (vestibular neuritis), a randomized controlled trial demonstrated methylprednisolone significantly improved peripheral vestibular function (62% vs. 39% with placebo), though Cochrane analysis found insufficient evidence to formally recommend it; a 3-week tapering regimen (100mg/day, reduced by 20mg every 4 days) is commonly used in practice. For benign paroxysmal positional vertigo (BPPV), canalith repositioning maneuvers (Epley, Semont) remain the evidence-based standard of care. Ménière's disease management targets reduced endolymph production/increased absorption through dietary sodium restriction, diuretics, intratympanic gentamicin or steroids, and betahistine. Vestibular paroxysmia, caused by neurovascular compression of cranial nerve VIII, responds to low-dose carbamazepine (200-600mg/day), with gabapentin, valproic acid, and other anticonvulsants as alternatives. Vestibular migraine is managed similarly to migraine with aura using beta-blockers, valproic acid, or topiramate for prophylaxis. Episodic ataxia type 2 (CACNA1A mutation) is primarily treated with acetazolamide, though the aminopyridine derivative fampridine showed comparable efficacy (63% vs. 52% attack reduction) in the phase III EAT2TREAT trial. For cerebellar ataxia, aminopyridines and acetyl-DL-leucine (available in Vietnam as Tanganil) show emerging but still limited evidence, with ongoing trials (FACEG, ALCAT) expected to provide further data. Overall, the authors conclude that despite reasonably favorable spontaneous recovery in most peripheral vestibular disorders, high-quality evidence for many pharmacological interventions remains limited.
